INTRODUCTION
============

The incidence of gastroesophageal reflux disease (GERD) is increasing \[[@b1-ce-2016-133]\]. The true incidence of GERD may be underestimated because of the use of over-the-counter medications, such as antacids and proton pump inhibitors (PPIs). GERD not only adversely affects the patient's quality of life, but it is also a potential risk factor for the development of Barrett's esophagus and esophageal adenocarcinoma \[[@b1-ce-2016-133]\].

PPIs have been the mainstay of medical management of GERD. However, about 20% to 30% of patients with erosive reflux disease and 40% of patients with non-erosive reflux disease do not respond to PPIs. Moreover, no significant improvement is observed in symptoms with doubling the dose of PPIs \[[@b2-ce-2016-133]\]. The potential adverse effects of using PPIs for long term are also a matter of concern. These adverse effects include *Clostridium difficile* infection, bone fractures, hypomagnesemia, and higher incidence of chronic kidney disease in susceptible populations \[[@b3-ce-2016-133]-[@b5-ce-2016-133]\].

Anti-reflux surgery (ARS: open or laparoscopic fundoplication) has been the mainstay of treatment for patients not responsive to PPIs and documented reflux on pH-impedance analysis. However, a quarter of patients restart PPIs on long-term follow-up. Moreover, a requirement of re-intervention exists in about 15% and 30% patients after laparoscopic or conventional fundoplication, respectively \[[@b6-ce-2016-133]\]. Other adverse events known to occur with ARS include dysphagia, gas bloating, and inability to belch \[[@b7-ce-2016-133]\]. Patients with refractory GERD may not agree to ARS due to its invasive nature and possible adverse events as mentioned above. In a randomized controlled trial (RCT) comparing ARS with PPIs, the remission rates were similar in both arms at 5-year follow-up. However, adverse events, including gas bloating, dysphagia, and flatulence, were significantly higher in the ARS arm \[[@b8-ce-2016-133]\].

Laparoscopic fundoplication was the only surgical option for GERD until recently. The introduction of magnetic sphincter augmentation (MSA) has marked the beginning of a new era in the surgical management of these patients. MSA device (LINX System; Torax Medical Inc., Shoreview, MN, USA) consists of a small flexible band of interlinked titanium beads with magnetic cores. It is placed laparoscopically around the lower esophageal sphincter (LES) without altering hiatal or gastric anatomy. The beads separate during swallowing as well as during belching or vomiting \[[@b9-ce-2016-133]\]. Therefore, adverse events, such as dysphagia, inability to belch, and vomiting, are less frequent as compared to the traditional ARS. A published literature suggests that MSA is equally effective with less procedure duration as compared to ARS \[[@b10-ce-2016-133]\]. The most common adverse event with MSA procedure is dysphagia for which the device may have to be removed in some patients. Recently, a case of endoluminal perforation has been reported with MSA resulting in severe dysphagia \[[@b11-ce-2016-133]\].

With the increasing prevalence of GERD, there is an unmet need for minimally invasive treatment modalities for patients who do not respond to PPIs and are unwilling for ARS. Minimally invasive endoscopic options for GERD have been in place for more than a decade now. Some of these have not stood the test of time either due to inefficacy, non-durable response, or safety issues. These include implantation and injection devices (Enteryx \[Boston Scientific Corp, Natick, MA, USA\], Gatekeeper \[Medtronic, Minneapolis, MN, USA\], Plexiglas microspheres \[Artes Medical, San Diego, CA, USA\]) and several endoscopic apposition devices (EndoCinch \[Bard Medical, Covington, GA USA\], NDO Plicator \[NDO Surgical, Mansfield, MA, USA\]). The currently available endoscopic anti-reflux modalities (EARMs) include radiofrequency ablation (RFA), transoral incisionless fundoplication (TIF), medigus ultrasonic surgical endostapler (MUSE), and anti-reflux mucosectomy (ARMS) ([Fig. 1](#f1-ce-2016-133){ref-type="fig"}).

RADIOFREQUENCY ABLATION
=======================

The Stretta system (Mederi Therapeutics, Norwalk, CT, USA) uses application of radiofrequency energy via a needle balloon catheter system to the LES muscle and gastric cardia ([Fig. 2A](#f2-ce-2016-133){ref-type="fig"}). Multiple applications (up to 14) are given by changing the position of the balloon catheter assembly using catheter rotation and by changing its linear position in relation to the Z line ([Fig. 2B](#f2-ce-2016-133){ref-type="fig"}). The system typically delivers low power (5 W) energy with a thermocouple that ensures avoidance of high temperatures at muscularis (\>85°C) and mucosal levels (\>50°C). In addition, regular irrigation prevents any injury to the mucosa.

The mechanism of action is not completely elucidated. The proposed mechanisms include hypertrophy of the muscularis propria and reduced transient LES relaxations after RFA \[[@b12-ce-2016-133],[@b13-ce-2016-133]\]. Fibrosis at the gastroesophageal junction (GEJ) was considered as one of the modes of action. However, in a recent study, reduced GEJ compliance was found after RFA, which normalized on administration of sildenafil (smooth muscle relaxant), suggesting against the development of GEJ fibrosis after RFA \[[@b14-ce-2016-133]\].

The efficacy and durability of response with RFA in patients with GERD are evident by multiple RCTs and a systemic review \[[@b15-ce-2016-133]-[@b20-ce-2016-133]\]. In a long-term follow-up study, normalization of GERD health-related quality of life (GERD-HRQL) was achieved in 72% and 50% or greater reduction in PPI use occurred in 64% of patients at 10-year follow-up. Importantly, regression of Barrett's metaplasia was observed in 85% of biopsied patients \[[@b19-ce-2016-133]\].

In a systemic review including 1,441 patients from 18 studies, RFA therapy significantly improved heartburn scores and GERD-HRQL. Esophageal acid exposure time (EAET) decreased from a pre-procedure De-Meester score of 44.4 to 28.5 (*p*=0.007) \[[@b20-ce-2016-133]\]. The guidelines by the Society of American Gastrointestinal and Endoscopic Surgeons advocate the use of RFA in selected patients with GERD \[[@b21-ce-2016-133]\].

In contrast to the above literature, more recently published systemic review and meta-analyses, which included four RCTs, showed no difference between Stretta versus sham or PPIs in patients with GERD for the outcomes of EAET, LES pressure, ability to stop PPIs, or HRQL \[[@b22-ce-2016-133]\]. However, one of the criteria for efficacy in this review was normalization of pH (pH \<4 exposure time \<4%), which is rather stringent and not achieved even in patients who respond successfully to PPIs \[[@b23-ce-2016-133]\]. Moreover, the authors agree that the overall quality of evidence from RCTs on the efficacy of the Stretta procedure was extremely low.

There are few comparative studies between RFA and ARS (laparoscopic Toupet fundoplication) with contradictory results. In a prospective observational study, ARS and the Stretta procedure were equally effective in controlling GERD symptoms and reducing the use of PPIs \[[@b24-ce-2016-133]\]. In another study, the Stretta procedure was equal to ARS in controlling extraesophageal manifestations of GERD \[[@b25-ce-2016-133]\]. By contrast, Stretta was inferior to ARS for typical and respiratory symptoms associated with GERD in two other studies \[[@b26-ce-2016-133],[@b27-ce-2016-133]\]. Unfortunately, no RCTs to date have compared both the modalities.

One of the major advantages of Stretta over other EARMs is that it can be performed under conscious sedation as a day care procedure. Moreover, the procedure duration is short, and its safety and efficacy have been studied more than in any other EARMs. It also does not hinder subsequent therapy like ARS if required. The major drawbacks of RFA are the wide variability in response rates (16% to 86%) and the low rate of improvement in objective parameters like normalization of EAET \[[@b18-ce-2016-133]\]. Complete cessation of PPI use is achieved in only 40% of patients on long-term follow-up \[[@b19-ce-2016-133]\]. Patients with large hiatal hernia and severe esophagitis are not ideal candidates for RFA.

Adverse events noted with RFA therapy are usually mild and include chest pain (50%), transient fever, and esophageal ulcers. Gastroparesis has been rarely reported presumably due to inadvertent vagal nerve injury \[[@b28-ce-2016-133]\].

TRANSORAL INCISIONLESS FUNDOPLICATION
=====================================

The TIF procedure is a minimally invasive treatment for GERD and follows the principles of ARS, i.e., by reducing a hiatal hernia (≤2 cm) and creating a valve 2 to 4 cm in length and greater than 270º circumferential wrap. It is performed in the outpatient setting under general anesthesia. The TIF procedure has undergone several modifications since its introduction about a decade ago ([Table 1](#t1-ce-2016-133){ref-type="table"}). In this procedure, a fundoplication device (EsophyX; EndoGastric Solutions, Redmond, WA, USA) ([Fig. 3A](#f3-ce-2016-133){ref-type="fig"}) is used with a flexible endoscope and gently introduced into the stomach under visualization ([Fig. 3B](#f3-ce-2016-133){ref-type="fig"}). The endoscope along with the device is retroflexed, and a helical retractor is engaged into the tissue slightly distal to the Z line ([Fig. 3C](#f3-ce-2016-133){ref-type="fig"}). The fundus of the stomach is folded up and around the distal esophagus utilizing the tissue mold and chassis of the device. Subsequently, an integrated suction apparatus grasps the distal esophagus and positions it below the diaphragm. H-shaped fasteners, made of polypropylene, are then delivered through apposed layers of esophageal and fundus tissue to anchor the repair. This process is repeated to create a full thickness, partial circumference, and gastroesophageal fundoplication ([Fig. 3D](#f3-ce-2016-133){ref-type="fig"}, [E](#f3-ce-2016-133){ref-type="fig"}). Approximately 20 fasteners are implanted during the procedure to create fusion of the esophageal and fundus tissues and form the valve.

Multiple studies including five RCTs and two systemic reviews have shown the efficacy of TIF \[[@b29-ce-2016-133]-[@b34-ce-2016-133]\]. In a systemic review including 963 patients from 18 studies (five RCTs and 13 prospective observational), the pooled relative risk of response rate to TIF versus PPIs/sham was 2.44 (95% confidence interval, 1.25 to 4.79; *p*=0.0009) in RCTs in the intention-to-treat analysis. The total number of refluxes was reduced after TIF compared with the PPIs/sham group. However, the EAET and acid reflux episodes were not significantly improved, and PPI usage increased with time during the long-term follow-up. The incidence of severe adverse events consisting of gastrointestinal perforation and bleeding was 2.4% \[[@b34-ce-2016-133]\].

The durability of response is evident in a recent study with a 6-year follow-up. PPIs were stopped or halved in 87.8% and 84.4% at 2 and 3 years, respectively, with stable response up to 6 years \[[@b35-ce-2016-133]\].

One study compared TIF with ARS (Nissen and Toupet fundoplication). Both groups showed similar reduction in symptom frequency and severity. However, patients undergoing TIF exhibited significantly shorter operative times and length of stay \[[@b36-ce-2016-133]\].

The factors predicting good outcome with TIF include pre-procedure Hill grade I to II, no or small hiatal hernia (≤2 cm), normal esophageal motility, number of fasteners deployed, persistence of typical symptoms on PPIs (GERD HRQL score ≥15), and an objectively confirmed diagnosis of GERD \[[@b35-ce-2016-133],[@b37-ce-2016-133]\].

The advantages of TIF are that it is less invasive than ARS, is performed in outpatient settings, has fewer adverse effects, and does not preclude the chances of revision ARS if required \[[@b38-ce-2016-133]\]. Serious adverse events reported with TIF are rare and include perforation, pneumothorax, and bleeding \[[@b39-ce-2016-133]\].

With respect to symptom response and safety profile, TIF appears promising. However, normalization of EAET and complete cessation of PPIs are not achieved in long-term follow-up studies. In one study, only one-third of patients were completely off PPIs at 6-year follow-up \[[@b35-ce-2016-133]\].

MEDIGUS ULTRASONIC SURGICAL ENDOSTAPLER
=======================================

The MUSE (Medigus, Omer, Israel) is an endoscopic stapling device for transoral partial fundoplication. The complete device consists of a flexible endoscope, an endostapler, a video camera, and an ultrasound transducer ([Fig. 4](#f4-ce-2016-133){ref-type="fig"}). After inserting the device, retroflexion is performed in the stomach, and the device is withdrawn until the chosen stapling level (usually 3 cm above the Z line). Subsequently, the stapler is fired under the guidance of ultrasonic gap finder. The process is repeated to form a flap akin to laparoscopic fundoplication.

In a multicenter study including 66 patients, significant improvement in GERD-HRQL score was found in 73% of patients at 6 months after the procedure. About 65% of patients completely discontinued PPIs, and significant reduction in PPI dosage was observed in 56% of patients who still continued PPIs. EAET also reduced at 6 months \[[@b40-ce-2016-133]\].

Two severe adverse events including empyema/pneumothorax and upper gastrointestinal hemorrhage occurred in initial 24 subjects. The technique and device were then modified, and no serious adverse events were noted in subsequent patients.

Long-term results with this device have been published recently. In a long-term follow-up study, 69.4% were off PPIs at 4 years after the TIF procedure. A significant reduction in GERD-HRQL scores and the daily dosage of GERD medications was found \[[@b41-ce-2016-133]\].

Although emerging data with MUSE is encouraging, it is a relatively new procedure with limited long-term data on efficacy and safety. The ideal stapling site for this procedure is also not well known. An *ex vivo* study concluded that the ideal stapling site was at 3 cm above the GEJ \[[@b42-ce-2016-133]\]. However, the results need to be interpreted with caution as it is an *ex vivo* study.

ENDOSCOPIC FULL THICKNESS PLICATION (GERx)
==========================================

Initial studies of endoscopic full thickness plication (EFTP) were carried out with the Plicator device (Ethicon Endosurgery, Somerville, NJ, USA). However, this device is no longer available commercially. Recently, a new device based on plicator technology and produced by a different manufacturer has been introduced (GERDx System; G-SURG GmbH, Seeon-Seebruck, Germany) ([Fig. 5](#f5-ce-2016-133){ref-type="fig"}).

The procedure of EFTP itself has undergone several modifications since its initial introduction for GERD. A single suture was initially placed below GEJ. However, the results were not impressive as a single suture could not create an effective anti-reflux barrier \[[@b43-ce-2016-133]\]. Subsequently, the technique was modified, and multiple plication implants were placed to achieve a robust antireflux valve \[[@b44-ce-2016-133]-[@b46-ce-2016-133]\].

In a prospective study including 36 patients, symptoms improved in 92% and 89% of patients were off PPIs at 1-year follow-up after EFTP with one or more plication implants. There was also a significant reduction in EAET \[[@b44-ce-2016-133]\]. Similar results were produced in a multicenter study, where 75% of patients had \>50% improvement in GERD-HRQL and 70% of patients were off daily PPIs at 6 months. The subjective improvement and elimination of need for daily PPI usage persisted at 1-year follow-up \[[@b45-ce-2016-133],[@b46-ce-2016-133]\]. Postprocedure adverse events were minor and included pain in the abdomen, shoulder, and chest. There were no long-term adverse events.

ANTI-REFLUX MUCOSECTOMY
=======================

The ARMS procedure is based on the principle that after mucosal resection, the mucosal healing results in scar formation. This in turn results in shrinkage and remodeling of gastric cardia flap valve; thereby, reducing reflux events. Although the first case was performed more than a decade ago, the results of the first series were published recently \[[@b47-ce-2016-133],[@b48-ce-2016-133]\].

The technique of ARMS procedure (as described by Inoue et al. \[[@b48-ce-2016-133]\]) involves resection of gastric (about 2 cm) and esophageal mucosa (about 1 cm) in crescentic fashion. The field of resection is initially marked by an electrocautery knife. Subsequently, a solution of saline mixed with indigo-carmine dye is injected submucosally to raise a wheal ([Fig. 6A](#f6-ce-2016-133){ref-type="fig"}). In the next step, mucosal resection is performed along the lesser curvature either by endoscopic mucosal resection or submucosal dissection ([Fig. 6B](#f6-ce-2016-133){ref-type="fig"}, [C](#f6-ce-2016-133){ref-type="fig"}). A gap equal to twice the scope diameter is left along the greater curvature side. Circumferential resection of the mucosa is avoided to prevent stricture formation as was noted in initial few cases of this series. Any bleeding during the procedure is controlled by coagrasper ([Fig. 6D](#f6-ce-2016-133){ref-type="fig"}, [E](#f6-ce-2016-133){ref-type="fig"}). In the only published pilot study including 10 patients, there was reduction in EAET and improvement in flap valve grade observed on endoscopic examination. In addition, all the patients could discontinue PPI after the ARMS therapy \[[@b47-ce-2016-133]\].

The advantages of ARMS include no requirement of any propriety devices and no endoprostheses are left *in situ*. However, no randomized studies have been conducted, and durability of response is unknown. In addition, the amount of mucosa to be resected for optimal results is not known and needs further evaluation. As with other EARMs, patients with large hiatal hernia are not suitable candidates for ARMS procedure.

EARMs: THE PROS AND CONS
========================

EARMs are emerging as minimally invasive treatment option for patients with GERD. Reduced hospital stay and adverse events were observed compared with the conventional ARS, making them an attractive option for patients with GERD. Long-term follow-up data with evidence of durable response are available for RFA (Stretta) and emerging for transoral fundoplication techniques as well (TIF and MUSE) ([Table 2](#t2-ce-2016-133){ref-type="table"}). However, certain drawbacks with EARMs are noteworthy. First, these devices have been tried in select patients with minimal esophageal inflammation and small hiatus hernia. Second, although symptom response is reasonably good, objective data (like EAET) are less impressive. The current literature suggests that EARMs do reduce EAET, but often do not normalize the same. Normalization of EAET is no doubt a difficult goal to achieve, but cannot be ignored due to potential long-term consequences like Barrett's esophagus and esophageal adenocarcinoma. Similarly, the need of PPI use is reduced but not eliminated completely in substantial proportion of patients undergoing endoscopic therapy. Lastly, long-term data with some of the recently introduced EARMs are not sufficient and comparative studies between different endoscopic modalities are lacking. Therefore, the best EARM is not known ([Table 2](#t2-ce-2016-133){ref-type="table"}).

The definition and measures to analyse efficacy have been variable in different studies. They must be standardized to compare results between different studies or different modalities. Failure to normalize EAET or complete elimination of daily PPI usage may be regarded as therapeutic failure. On the other hand, reduction in EAET and elimination of daily PPI usage or reduction in dosage of PPIs after endotherapy may be regarded as successful outcome. This is exemplified by the contrasting results between two recently published meta-analyses where the first one depicted good outcomes with RFA \[[@b20-ce-2016-133]\], whereas the latter published meta-analysis concluded no benefit over sham procedure \[[@b22-ce-2016-133]\].

ENDOTHERAPY FOR GERD: 'OPTIMIZING' THE 'OUTCOMES'
=================================================

The outcomes with EARMs have improved, and adverse events reduced as a result of modification of techniques as well as up-gradation of available devices. Increasing the number of fasteners and plication implants have been clearly shown to improve results with TIF and EFTP, respectively \[[@b35-ce-2016-133],[@b37-ce-2016-133]\]. Likewise, allowing second session of RFA augmented the results of Stretta in a randomized study \[[@b15-ce-2016-133]\]. Using a modified technique resulted in minimization of therapeutic misadventure with ultrasonic endostapler device \[[@b41-ce-2016-133]\]. Further optimization of endoscopic devices and procedural techniques should enhance the outcomes with EARMs in the future.

In addition to the technique and devices, pre-procedure evaluation and careful patient selection is of paramount importance to obtain optimal results with EARMs. Minimum pre-procedure work up should include an esophagogastroduodenoscopy, pH-impedance analysis, and esophageal manometry. Patients with large hiatal hernia (\>2 cm), severe esophagitis (grades C and D), Barrett's esophagus, negative pH-impedance analysis, and ineffective esophageal peristalsis may not be suitable candidates for EARMs.

CONCLUSIONS
===========

PPIs remain the cornerstone of medical management of GERD, and EARMs are not meant to replace PPIs altogether. They may bridge the unmet gap between PPIs and ARS. However, more studies with long-term follow-up and randomized comparisons are required to establish the role of EARMs in the management of GERD. Studies assessing the predictive factors for response or non-response to EARMs will help in minimizing failures and maximizing efficacy.
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![Currently available endoscopic anti-reflux modalities. Stretta (Mederi Therapeutics), EsophyX (EndoGastric Solutions), MUSE (Medigus), GERDx (G-SURG GmbH).](ce-2016-133f1){#f1-ce-2016-133}

![(A) Radiofrequency device (Stretta; Mederi Therapeutics) with a four-needle balloon catheter system. (B) Depiction of Stretta procedure-radiofrequency energy delivered to gastroesophageal junction muscle at multiple sites.](ce-2016-133f2){#f2-ce-2016-133}

![(A) Transoral fundoplication device (EsophyX; EndoGastric Solutions) and its components. (B) Retroflexed device in the stomach. (C) Engaging the helical retractor into the tissue. (D) Application of H-shaped polypropylene fasteners (about 20). (E) Creation of full-thickness partial circumference fundoplication.](ce-2016-133f3){#f3-ce-2016-133}

![MUSE (Medigus) endoscopic stapling device and its components.](ce-2016-133f4){#f4-ce-2016-133}

![(A, B) Full thickness endoscopic plication device (GERDx; G-SURG GmbH). (C) GERDx inside the stomach in retroflexed view. (D) Advancement of 'Drill helix' into gastric cardia. (E) Closure of the device arms after gathering tissue and deployment of suture. (F) Reopening of the device arms after plication implant.](ce-2016-133f5){#f5-ce-2016-133}

![(A) Submucosal injection of saline with indigo-carmine at gastric cardia. (B) Application of snare over the mucosa with cap-endoscopic mucosal resection technique. (C) Completion of near circumferential (2/3) resection of gastric mucosa. (D) Actively bleeding spurter during mucosectomy procedure. (E) Effective control of bleeding vessel with coagrasper.](ce-2016-133f6){#f6-ce-2016-133}

###### 

The Evolution of the Transoral Incisionless Fundoplication

  Name                                        Fastener placement                                                    Plication type    Wrap
  ------------------------------------------- --------------------------------------------------------------------- ----------------- ------
  Endoluminal fundoplication                  Below Z line                                                          Gastrogastric     No
  Transoral incisionless iundoplication 1.0   Above Z line 1 cm                                                     Esophagogastric   No
  Transoral incisionless fundoplication 2.0   1-3 cm above Z line; more length along greater curve of the stomach   Esophagogastric   Yes

###### 

Comparison of Available Endoscopic Antireflux Therapies

  Variable                                         Stretta                                                                         TIF                                                          MUSE
  ------------------------------------------------ ------------------------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------
  Treatment response (complete cessation of PPI)   16%-80% \[[@b14-ce-2016-133],[@b15-ce-2016-133]\]                               32%-82% \[[@b34-ce-2016-133]\]                               65%^[a)](#tfn1-ce-2016-133){ref-type="table-fn"}^-83.8%^[b)](#tfn2-ce-2016-133){ref-type="table-fn"}^ \[[@b39-ce-2016-133],[@b40-ce-2016-133]\]
  Durability of response (longest follow-up)       41% at 10 years \[[@b18-ce-2016-133]\]                                          36% at 6 years \[[@b33-ce-2016-133]\]                        69% at 4 years^[b)](#tfn2-ce-2016-133){ref-type="table-fn"}^ \[[@b40-ce-2016-133]\]
  Normalization of esophageal acid exposure        5%-75% \[[@b14-ce-2016-133],[@b17-ce-2016-133]\]                                37%-89% \[[@b32-ce-2016-133]\]                               37.1% \[[@b40-ce-2016-133]\]
  Serious adverse events                           Aspiration pneumonia, gastroparesis \[[@b14-ce-2016-133],[@b16-ce-2016-133]\]   Bleeding, perforation, pneumothorax \[[@b34-ce-2016-133]\]   Bleeding, pneumothorax, pneumomediastinum \[[@b40-ce-2016-133]\]

TIF, transoral incisionless fundoplication; MUSE, medigus ultrasonic surgical endostapler; PPI, proton pump inhibitor.

Completely off PPI;

Off daily PPI.
